Institutional owners may consider drastic action as Foghorn Therapeutics Inc.’s (NASDAQ:FHTX) recent $42 million decline adds to long-term losses.

Key ideas

• Given the significant institutional ownership in the stock, Foghorn Therapeutics’ stock price could be vulnerable to their business decisions.
• The top 5 shareholders own 53% of the company
• By using analyst forecast data as well as ownership research, one can better assess a company’s future performance.

To get an idea of ​​who really controls Foghorn Therapeutics Inc. (NASDAQ: FHTX), it’s important to understand the company’s ownership structure. The group holding the largest number of shares in the company, around 35% to be precise, are institutions. In other words, the group will benefit the most if the stock rises (or lose the most if the stock goes down).

And institutional investors suffered the biggest losses after the company’s stock price fell 13% last week. The recent loss, which comes on top of a 41% year-over-year loss for shareholders, may not please this group of investors. Often called “market players”, institutions exercise significant power to influence the price dynamics of any action. Consequently, if the downward trend continues, institutions could face pressures to sell Foghorn Therapeutics, which could have negative implications for individual investors.

Let’s take a closer look at each Foghorn Therapeutics owner type, starting with the table below.

Check out our latest analysis for Foghorn Therapeutics

What does institutional ownership tell us about Foghorn Therapeutics?

Institutional investors typically compare their own returns to those of a commonly followed index. They therefore generally consider buying larger companies included in the relevant benchmark index.

As you can see, institutional investors own a significant stake in Foghorn Therapeutics. This may indicate that the company has a certain degree of credibility with the investment community. However, it is best to be wary of the supposed validation provided by institutional investors. They, too, are sometimes wrong. If multiple institutions change their views on a stock at the same time, the stock price could fall quickly. So it’s worth taking a look at Foghorn Therapeutics’s earnings history below. Of course, it’s the future that really matters.

Our data indicates that hedge funds own 5.3% of Foghorn Therapeutics. This catches my attention because hedge funds sometimes try to influence management or make changes that will create short-term value for shareholders. Looking at our data, we can see that the largest shareholder is Flagship Pioneering, Inc with 23% of the shares outstanding. FMR LLC is the second largest shareholder with 11% of the common stock, and Eli Lilly and Company owns approximately 7.2% of the company’s stock. Additionally, CEO Adrian H. Gottschalk owns 0.9% of the company’s shares.

Our research also highlighted that approximately 53% of the company is controlled by the top five shareholders, suggesting that these owners have significant influence over the company.

While it makes sense to study data on institutional ownership of a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. Many analysts cover the stock, so you can look at growth forecasts quite easily.

Insider ownership of Foghorn Therapeutics

The definition of an insider may differ slightly between countries, but board members still count. The management of the company answers to the board of directors and the latter must represent the interests of the shareholders. Notably, it sometimes happens that high-level executives themselves sit on the board of directors.

Internal ownership is positive when it indicates that management thinks like the true owners of the company. However, strong internal ownership can also give immense power to a small group within the company. This can be negative in certain circumstances.

Our most recent data indicates that insiders own some shares of Foghorn Therapeutics Inc.. The company has a market cap of just US$310m, and insiders own US$25m worth of stock, in their own names. It’s good to see investment from insiders, but it might be worth checking to see if those insiders have been buying.

Consumer property

With a 21% stake, the general public, consisting mainly of individual investors, has some influence over Foghorn Therapeutics. Even if this size of ownership may not be sufficient to tip a political decision in their favor, they can nevertheless have a collective impact on business policies.

Private Equity Ownership

With a 23% stake, private equity firms are able to play a role in shaping corporate strategy with a focus on value creation. This might appeal to some, because private equity is sometimes an activist in holding management accountable. But other times, private equity sells itself, after taking the company public.

Public company ownership

It appears to us that public companies own 7.2% of Foghorn Therapeutics. This may be a strategic interest and the two companies may have related business interests. They might have merged. This exploitation probably deserves further investigation.

Next steps:

It’s always helpful to think about the different groups that own shares in a company. But to better understand Foghorn Therapeutics, we need to consider many other factors. Please note that Foghorn Therapeutics displays 4 warning signs in our investment analysis and one of them is a bit worrying…

If you are like me, you may want to ask if this company will grow or decrease. Fortunately, you can consult this free report presenting analysts’ forecasts for its future.

NB: The figures for this article are calculated from data from the last twelve months, which refer to the 12 -month period ending on the last day of the month when the financial statements are dated. This may not be consistent with the annual report figures for the whole year.

Returns on this article? Worried about content? Get in touch with us directly. You can also send an email to the editorial team (AT) Simplywallst.com.

This article by Simply Wall St is general. We provide comments based on historical data and analyst forecasts only using an impartial methodology and our articles are not intended to build financial advice. It does not constitute a recommendation to purchase or sell shares and do not take into account your objectives or your financial situation. Our goal is to offer you a long -term targeted analysis based on fundamental data. Note that our analysis may not take into account the latest announcements of companies sensitive to prices or qualitative elements. Simply Wall St has no position on the actions mentioned.

Returns on this article? Worried about content? Contact us directly. You can also send an e-mail to [email protected]